Diabetes mellitus is a major health problem that threatens the whole world. According to WHO reports, the prevalence of diabetic patients in egyptis expected to increase from 2,623,000 in 2000 to be 6,726,000 in 2030. Metformin is the first line drug for type 2 diabetes mellitus, which can be used alone or in combination with other drugs. However, the concomitant use of metformin with stevia needs more investigation to clarify the role of this combination as a new strategy in type 2 diabetes mellitus. Type 2 diabetes mellitus was induced in rats by i.p. injection of STZ and NA. Animals were divided into five groups, each contains 8 rats. Group I: negative control, group II: diabetic control received saline, group III: diabetic rats received 400 mg/kg/day stevia aqueous extract, group IV: diabetic rats received metformin 250 mg/kg/day, group V: diabetic rats received stevia 400 mg/kg/day + metformin 250 mg/kg/day. After 3 weeks blood samples were collected, animals were sacrificed and tissue samples were collected. Biochemical parameters including FBG, serum insulin, serum DPP-4, TC, TG, LDL, HDL, GSH and MDA were measured by colorimetric and ELISA methods. Both stevia and metformin significantly reduced FBG level. While serum insulin significantly increased. Serum DPP-4 was significantly reduced in all treated groups, concerning lipid profile, stevia and metformin significantly lowered TC, TG, LDLand increased HDL. Both stevia and metformin significantly decreased MDA and increased GSH compared to diabetic rats. In addition, stevia significantly improved the antidiabetic effects of metformin. Stevia has an antihyperglycemic effect and could increase the antidiabetic activity of metformin. DPP-4 attenuation, antioxidant and insulin-sensitizing effects may be involved in the antidiabetic action of stevia. Regarding lipid profile stevia showed hypolipidemic effect.

Diabetes mellitus is a major health problem that threatens the whole world. According to WHO reports, the prevalence of diabetic patients in egyptis expected to increase from 2,623,000 in 2000 to be 6,726,000 in 2030. Metformin is the first line drug for type 2 diabetes mellitus, which can be used alone or in combination with other drugs. However, the concomitant use of metformin with stevia needs more investigation to clarify the role of this combination as a new strategy in type 2 diabetes mellitus. Type 2 diabetes mellitus was induced in rats by i.p. injection of STZ and NA. Animals were divided into five groups, each contains 8 rats. Group I: negative control, group II: diabetic control received saline, group III: diabetic rats received 400 mg/kg/day stevia aqueous extract, group IV: diabetic rats received metformin 250 mg/kg/day, group V: diabetic rats received stevia 400 mg/kg/day + metformin 250 mg/kg/day. After 3 weeks blood samples were collected, animals were sacrificed and tissue samples were collected. Biochemical parameters including FBG, serum insulin, serum DPP-4, TC, TG, LDL, HDL, GSH and MDA were measured by colorimetric and ELISA methods. Both stevia and metformin significantly reduced FBG level. While serum insulin significantly increased. Serum DPP-4 was significantly reduced in all treated groups, concerning lipid profile, stevia and metformin significantly lowered TC, TG, LDLand increased HDL. Both stevia and metformin significantly decreased MDA and increased GSH compared to diabetic rats. In addition, stevia significantly improved the antidiabetic effects of metformin. Stevia has an antihyperglycemic effect and could increase the antidiabetic activity of metformin. DPP-4 attenuation, antioxidant and insulin-sensitizing effects may be involved in the antidiabetic action of stevia. Regarding lipid profile stevia showed hypolipidemic effect.

Diabetes mellitus is a major health problem that threatens the whole world. According to WHO reports, the prevalence of diabetic patients in egyptis expected to increase from 2,623,000 in 2000 to be 6,726,000 in 2030. Metformin is the first line drug for type 2 diabetes mellitus, which can be used alone or in combination with other drugs. However, the concomitant use of metformin with stevia needs more investigation to clarify the role of this combination as a new strategy in type 2 diabetes mellitus. Type 2 diabetes mellitus was induced in rats by i.p. injection of STZ and NA. Animals were divided into five groups, each contains 8 rats. Group I: negative control, group II: diabetic control received saline, group III: diabetic rats received 400 mg/kg/day stevia aqueous extract, group IV: diabetic rats received metformin 250 mg/kg/day, group V: diabetic rats received stevia 400 mg/kg/day + metformin 250 mg/kg/day. After 3 weeks blood samples were collected, animals were sacrificed and tissue samples were collected. Biochemical parameters including FBG, serum insulin, serum DPP-4, TC, TG, LDL, HDL, GSH and MDA were measured by colorimetric and ELISA methods. Both stevia and metformin significantly reduced FBG level. While serum insulin significantly increased. Serum DPP-4 was significantly reduced in all treated groups, concerning lipid profile, stevia and metformin significantly lowered TC, TG, LDLand increased HDL. Both stevia and metformin significantly decreased MDA and increased GSH compared to diabetic rats. In addition, stevia significantly improved the antidiabetic effects of metformin. Stevia has an antihyperglycemic effect and could increase the antidiabetic activity of metformin. DPP-4 attenuation, antioxidant and insulin-sensitizing effects may be involved in the antidiabetic action of stevia. Regarding lipid profile stevia showed hypolipidemic effect.

Diabetes mellitus is a major health problem that threatens the whole world. According to WHO reports, the prevalence of diabetic patients in egyptis expected to increase from 2,623,000 in 2000 to be 6,726,000 in 2030. Metformin is the first line drug for type 2 diabetes mellitus, which can be used alone or in combination with other drugs. However, the concomitant use of metformin with stevia needs more investigation to clarify the role of this combination as a new strategy in type 2 diabetes mellitus. Type 2 diabetes mellitus was induced in rats by i.p. injection of STZ and NA. Animals were divided into five groups, each contains 8 rats. Group I: negative control, group II: diabetic control received saline, group III: diabetic rats received 400 mg/kg/day stevia aqueous extract, group IV: diabetic rats received metformin 250 mg/kg/day, group V: diabetic rats received stevia 400 mg/kg/day + metformin 250 mg/kg/day. After 3 weeks blood samples were collected, animals were sacrificed and tissue samples were collected. Biochemical parameters including FBG, serum insulin, serum DPP-4, TC, TG, LDL, HDL, GSH and MDA were measured by colorimetric and ELISA methods. Both stevia and metformin significantly reduced FBG level. While serum insulin significantly increased. Serum DPP-4 was significantly reduced in all treated groups, concerning lipid profile, stevia and metformin significantly lowered TC, TG, LDLand increased HDL. Both stevia and metformin significantly decreased MDA and increased GSH compared to diabetic rats. In addition, stevia significantly improved the antidiabetic effects of metformin. Stevia has an antihyperglycemic effect and could increase the antidiabetic activity of metformin. DPP-4 attenuation, antioxidant and insulin-sensitizing effects may be involved in the antidiabetic action of stevia. Regarding lipid profile stevia showed hypolipidemic effect.

Diabetes mellitus is a major health problem that threatens the whole world. According to WHO reports, the prevalence of diabetic patients in egyptis expected to increase from 2,623,000 in 2000 to be 6,726,000 in 2030. Metformin is the first line drug for type 2 diabetes mellitus, which can be used alone or in combination with other drugs. However, the concomitant use of metformin with stevia needs more investigation to clarify the role of this combination as a new strategy in type 2 diabetes mellitus. Type 2 diabetes mellitus was induced in rats by i.p. injection of STZ and NA. Animals were divided into five groups, each contains 8 rats. Group I: negative control, group II: diabetic control received saline, group III: diabetic rats received 400 mg/kg/day stevia aqueous extract, group IV: diabetic rats received metformin 250 mg/kg/day, group V: diabetic rats received stevia 400 mg/kg/day + metformin 250 mg/kg/day. After 3 weeks blood samples were collected, animals were sacrificed and tissue samples were collected. Biochemical parameters including FBG, serum insulin, serum DPP-4, TC, TG, LDL, HDL, GSH and MDA were measured by colorimetric and ELISA methods. Both stevia and metformin significantly reduced FBG level. While serum insulin significantly increased. Serum DPP-4 was significantly reduced in all treated groups, concerning lipid profile, stevia and metformin significantly lowered TC, TG, LDLand increased HDL. Both stevia and metformin significantly decreased MDA and increased GSH compared to diabetic rats. In addition, stevia significantly improved the antidiabetic effects of metformin. Stevia has an antihyperglycemic effect and could increase the antidiabetic activity of metformin. DPP-4 attenuation, antioxidant and insulin-sensitizing effects may be involved in the antidiabetic action of stevia. Regarding lipid profile stevia showed hypolipidemic effect.

Diabetes mellitus is a major health problem that threatens the whole world. According to WHO reports, the prevalence of diabetic patients in egyptis expected to increase from 2,623,000 in 2000 to be 6,726,000 in 2030. Metformin is the first line drug for type 2 diabetes mellitus, which can be used alone or in combination with other drugs. However, the concomitant use of metformin with stevia needs more investigation to clarify the role of this combination as a new strategy in type 2 diabetes mellitus. Type 2 diabetes mellitus was induced in rats by i.p. injection of STZ and NA. Animals were divided into five groups, each contains 8 rats. Group I: negative control, group II: diabetic control received saline, group III: diabetic rats received 400 mg/kg/day stevia aqueous extract, group IV: diabetic rats received metformin 250 mg/kg/day, group V: diabetic rats received stevia 400 mg/kg/day + metformin 250 mg/kg/day. After 3 weeks blood samples were collected, animals were sacrificed and tissue samples were collected. Biochemical parameters including FBG, serum insulin, serum DPP-4, TC, TG, LDL, HDL, GSH and MDA were measured by colorimetric and ELISA methods. Both stevia and metformin significantly reduced FBG level. While serum insulin significantly increased. Serum DPP-4 was significantly reduced in all treated groups, concerning lipid profile, stevia and metformin significantly lowered TC, TG, LDLand increased HDL. Both stevia and metformin significantly decreased MDA and increased GSH compared to diabetic rats. In addition, stevia significantly improved the antidiabetic effects of metformin. Stevia has an antihyperglycemic effect and could increase the antidiabetic activity of metformin. DPP-4 attenuation, antioxidant and insulin-sensitizing effects may be involved in the antidiabetic action of stevia. Regarding lipid profile stevia showed hypolipidemic effect.

NULL

NULL

Hydrophilic matrices, especially HPMC based, are widely used to provide sustained delivery where drug release occurs mainly by diffusion. A 32 full factorial design was used to develop and evaluate HPMC matrix tablet for sustained delivery of diclofenac. The influences of polymer concentration/viscosity, diluent type/ratio, drug load/solubility, compression force and pH change on drug release were investigated. Ten tablet formulations were prepared using wet granulation. HPMC K15M (10-30% w/w) was used as the polymer forming matrix. The release kinetics, compatibility studies, lot reproducibility and effect on storage were discussed. Increasing polymer concentration and compression force showed antagonistic effect on release rate. Mannitol tends to increase release rate more than lactose. Reversing diluent ratio between lactose and MCC did not affect drug release. Changing pH resulted in burst release whereas drug solubility is pH independent. F1 showed similar release to VoltarenÆ SR and followed Higuchi model. Drug and polymer were compatible to each other. The formulation is stable at long and intermediate conditions with a significant increase in release rate at accelerated conditions due to water uptake and polymer swelling. The developed formulation was successful for a sustained delivery of diclofenac.

Hydrophilic matrices, especially HPMC based, are widely used to provide sustained delivery where drug release occurs mainly by diffusion. A 32 full factorial design was used to develop and evaluate HPMC matrix tablet for sustained delivery of diclofenac. The influences of polymer concentration/viscosity, diluent type/ratio, drug load/solubility, compression force and pH change on drug release were investigated. Ten tablet formulations were prepared using wet granulation. HPMC K15M (10-30% w/w) was used as the polymer forming matrix. The release kinetics, compatibility studies, lot reproducibility and effect on storage were discussed. Increasing polymer concentration and compression force showed antagonistic effect on release rate. Mannitol tends to increase release rate more than lactose. Reversing diluent ratio between lactose and MCC did not affect drug release. Changing pH resulted in burst release whereas drug solubility is pH independent. F1 showed similar release to VoltarenÆ SR and followed Higuchi model. Drug and polymer were compatible to each other. The formulation is stable at long and intermediate conditions with a significant increase in release rate at accelerated conditions due to water uptake and polymer swelling. The developed formulation was successful for a sustained delivery of diclofenac.